» Articles » PMID: 17089045

Molecular Mechanisms Underlying the Tumorigenesis of Colorectal Adenomas: Correlation to Activated K-ras Oncogene

Overview
Journal Oncol Rep
Specialty Oncology
Date 2006 Nov 8
PMID 17089045
Citations 11
Authors
Affiliations
Soon will be listed here.
Abstract

Mutations of K-ras gene have been demonstrated in 40-50% of colorectal cancer and large adenoma (>1 cm). This study was intended to clarify the correlation between the existence of K-ras oncogene and the pathological features of colorectal adenomas using our recently developed membrane arrays. Moreover, the downstream genes regulated by K-ras oncogene were explored to serve as potential biomarkers in the early diagnosis and risk assessment of patients with colorectal adenoma. Specimens were collected from 70 patients with colorectal adenoma. The alterations of K-ras oncogene were analyzed by direct sequencing and our constructed membrane arrays, respectively. The results of direct sequencing showed that 21 of 70 samples (30%) had K-ras gene mutations. The most frequently mutated sites included codons 12, 13, 15 and 18. Furthermore, activated K-ras oncogene was identified in 18 of 70 (25.7%) adenoma by membrane arrays. Statistical analyses showed that the membrane array had the accuracy of 90.0%, sensitivity of 88.9%, and specificity of 90.4%. The frequency of the mutational sites of K-ras gene was located as follows: codon 12, 100% (4/4); codon 13, 100% (4/4); codon 15, 75% (6/8); and codon 18, 100% (2/2). The analysis of the correlation between the experimental data and pathological characteristics of adenoma showed that activated K-ras oncogenes were significantly associated with the size, number and histology of adenomas (all P<0.001). Finally, we found the downstream genes activated by K-ras oncogene, including B-cell CLL/lymphoma 2 (BCL2), Homo sapiens H2A histone family, member Z (H2AFZ), Homo sapiens RAP1B, member of RAS oncogene family (RAP1B), Homo sapiens T-box 19 (TBX19), Homo sapiens E2F transcription factor 4, p107/p130-binding (E2F4) and matrix metallopeptidase 1 (MMP1), of which were overexpressed in most of all examined adenomas. These genes were then suggested to have functions involved in cell growth. The preliminary results indicated that the accuracy of membrane arrays was comparable to conventional DNA sequencing in the detection of activated K-ras oncogenes. Therefore, we propose that activated K-ras oncogene in colorectal adenomas may play an important role in the subsequent colorectal carcinogenesis through a group of K-ras-related molecular targets.

Citing Articles

Mutational analysis of driver genes defines the colorectal adenoma: in situ carcinoma transition.

Jungwirth J, Urbanova M, Boot A, Hosek P, Bendova P, Siskova A Sci Rep. 2022; 12(1):2570.

PMID: 35173208 PMC: 8850440. DOI: 10.1038/s41598-022-06498-9.


Colorectal Cancer: From Genetic Landscape to Targeted Therapy.

El Bali M, Bakkach J, Bennani Mechita M J Oncol. 2021; 2021:9918116.

PMID: 34326875 PMC: 8277501. DOI: 10.1155/2021/9918116.


TBX19 is overexpressed in colorectal cancer and associated with lymph node metastasis.

Ando J, Saito M, Imai J, Ito E, Yanagisawa Y, Honma R Fukushima J Med Sci. 2017; 63(3):141-151.

PMID: 29199261 PMC: 5792498. DOI: 10.5387/fms.2017-08.


miR-28-5p acts as a tumor suppressor in renal cell carcinoma for multiple antitumor effects by targeting RAP1B.

Wang C, Wu C, Yang Q, Ding M, Zhong J, Zhang C Oncotarget. 2016; 7(45):73888-73902.

PMID: 27729617 PMC: 5342021. DOI: 10.18632/oncotarget.12516.


Pancreatic cancer, treatment options, and GI-4000.

Hartley M, Bade N, Prins P, Ampie L, Marshall J Hum Vaccin Immunother. 2015; 11(4):931-7.

PMID: 25933185 PMC: 4514241. DOI: 10.1080/21645515.2015.1011017.